Site Search
Professionals 683 results
Capabilities 89 results
Region
Winston’s deep experience representing companies and investors across Latin America and the Caribbean has made the firm a “go-to” resource for the strategic development of our clients’ businesses and the vigorous protection of their interests in the region. With broad command of a diverse range of issues within the region’s key industry sectors, we advise Fortune 500 companies, government and quasi-governmental entities, financial institutions, private equity and other investors, domestic and international oil and gas exploration and production companies, refiners and shippers, and a range of commercial and infrastructure developers.
Industry
Insurance plays an essential role in risk mitigation for financial services companies. As risks evolve, questions often arise concerning the scope of insurance coverage and the interpretation and application of policy provisions. Winston’s insurance lawyers provide companies with best-in-class advice, corporate and transactional counsel, and, if need be, litigation defense in high-stakes coverage disputes and class actions. We have achieved excellent outcomes for our clients in matters involving a wide variety of insurance policies and claims, including cybersecurity, travel, long-term care, and annuities, among others. Moreover, we have experience in emerging issues and industries, such as blockchain technology and artificial intelligence, both of which present insurers with a unique and complicated set of risks and opportunities.
Industry
Winston is well regarded for deep and broad experience advising clients in the development, construction, financing and refinancing, acquisition, and operation of major infrastructure assets, including several award-winning deals and public-private-partnership (PPPs or P3s) projects in North America, Latin America, and Europe. Recognized for our ability to “take complex issues and boil them down to pragmatic solutions” (Chambers USA 2023), our team represents a diverse mix of participants and stakeholders in a broad range of investments and non-recourse/limited recourse financings, and we have experience working on many of the most complex projects, within aggressive time frames, while employing inventive solutions. Likewise, our lawyers help to identify and quantify roadblocks and risks at an early stage, so that we can help our clients—which include developers and sponsors, a full range of lenders and investors, project owners and operators, governments and their agencies, and other project counterparties—evaluate and, to the extent possible, mitigate or eliminate risk.
Experience 442 results
Experience
|August 19, 2025
Winston advised Ellipsis U.S. Onshore Holdings LLC, a portfolio company of the Westlawn Group, in connection with the acquisition of high-quality, non-operated working interests in the Permian Basin of Texas and New Mexico—adding approximately 4,000 barrels of oil equivalent per day in net production and over 600 gross remaining drilling locations. This strategic transaction strengthens Ellipsis’ Delaware Basin footprint and supports its strategy of scaling through high-margin, low-cost assets.
Experience
|August 18, 2025
Winston Represented Amphenol in Definitive Agreement to Acquire Trexon
Winston represented Amphenol Corporation (NYSE: APH), one of the world’s largest designers, manufacturers, and marketers of electrical, electronic, and fiber optic connectors and systems, as well as coaxial and high-speed specialty cables, in its definitive agreement to acquire Trexon, a leading provider of high-reliability interconnect and cable assemblies primarily serving the defense market. The acquisition is valued at approximately US$1B, subject to customary post-closing adjustments. Amphenol will finance the transaction with cash on hand and expects to close in the fourth quarter of 2025.
Experience
|August 12, 2025
US$2B Roper Technologies, Inc. Senior Notes Offering
Winston & Strawn LLP served as underwriters' counsel to BofA Securities, J.P. Morgan, and Wells Fargo Securities, as joint book-running managers, in connection with the registered public offering by Roper Technologies, Inc. of US$2B of senior notes, comprised of US$500M of its 4.250% senior notes due 2028, US$500M of its 4.450% senior notes due 2030 and US$1B of its 5.100% senior notes due 2035.
Insights & News 7,857 results
Seminar/CLE
|January 22, 2026
14th ITA-IEL-ICC Joint Conference on International Energy Arbitration – Houston
Imad Khan is a proud Co-Chair of The Institute for Transnational Arbitration (ITA), Institute for Energy Law (IEL) and International Chamber of Commerce (ICC) International Court of Arbitration 14th edition of what has become the premier conference on international arbitration in the energy sector. Speakers from around the globe and across the industry will gather to focus on the key issues in the field today.
Sponsorship
|October 9, 2025
Winston & Strawn Sponsors the 45th Annual Ray Garrett Jr. Corporate & Securities Law Institute
Winston & Strawn is proud to sponsor the 45th Annual Ray Garrett Jr. Corporate & Securities Law Institute at the Northwestern Pritzker School of Law in Chicago, IL.
Sponsorship
|September 18, 2025
Winston & Strawn Sponsors 21st Annual Boardroom Summit
Winston & Strawn is sponsoring the upcoming 21stAnnual Boardroom Summit & Board Committee Peer Exchange. This unique event will bring industry leading public company directors to discuss current trends, including shareholder activism, CEO succession strategies, and uses of AI in the boardroom.
Other Results 79 results
Law Glossary
What Statutes and Regulations Govern the Approval and Marketing of Biosimilars?
Congress passed the Biologics Price Competition and Innovation Act of 2009 (BPCIA) in 2010 an amendment of the Public Health Services Act. The BPCIA is codified at 42 U.S.C. § 262.
Law Glossary
What Exclusivity Periods Are Associated with Biosimilars?
An applicant may not submit an aBLA until four years after the reference product is licensed by the FDA. (See BPCIA § 351(k).) Further, any biosimilar licenses “may not be made effective” until 12 years after the reference product was licensed. (See BPCIA § 351(l).)